Q-omics provides the consensus-scored C12orf73 profile across patient tissues and cancer cell-line models. C12orf73 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, C12orf73 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, C12orf73 RNA expression shows 19,274 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where C12orf73 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C12orf73 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C12orf73 survival associations across molecular data types. C12orf73 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C12orf73 RNA expression–survival associations across cancer types. High C12orf73 expression shows unfavorable associations in LIHC, KICH, UVM, MESO, ESCA and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for C12orf73 RNA expression.
This table summarizes C12orf73 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C12orf73. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C12orf73 shows higher tumor expression in KIRC, COAD, BLCA, LIHC, KIRP and HNSC. The KIRC box plot shows higher C12orf73 RNA expression in tumor versus normal tissue (log2 FC = +0.461, t-test p < 0.001).
This table shows molecular features associated with C12orf73 in patient tissues and cancer cell lines. In patient samples, C12orf73 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C12orf73 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
